Gujarat Kidney And Super Speciality (NSE:GKSL) ROE %: 7.99% (As of Mar. 2026) — 74% Below Median


NSE:GKSL Gujarat Kidney And Super Speciality Ltd NSE:GKSL
18 GF Score
Price ₹129.23
! 5 Warning Signs
View Full Analysis

What is Gujarat Kidney And Super Speciality ROE %?

Gujarat Kidney And Super Speciality NSE:GKSL +0.83% 18 ROE % is 7.99% as of Mar. 2026, which is 74% below its 10-year median of 30.57. GuruFocus rates NSE:GKSL with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 625 Healthcare Providers & Services companies, Gujarat Kidney And Super Speciality ranks better than 74.08% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Gujarat Kidney And Super Speciality's annualized net income for the quarter that ended in Mar. 2026 was ₹201.7 Mil. Gujarat Kidney And Super Speciality's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₹2,525.1 Mil. Therefore, Gujarat Kidney And Super Speciality's annualized ROE % for the quarter that ended in Mar. 2026 was 7.99%.

The historical rank and industry rank for Gujarat Kidney And Super Speciality's ROE % or its related term are showing as below:

NSE:GKSL' s ROE % Range Over the Past 10 Years
Min: 10.65   Med: 30.57   Max: 43.79
Current: 14.01

During the past 4 years, Gujarat Kidney And Super Speciality's highest ROE % was 43.79%. The lowest was 10.65%. And the median was 30.57%.

NSE:GKSL's ROE % is ranked better than
74.08% of 625 companies
in the Healthcare Providers & Services industry
Industry Median: 5.84 vs NSE:GKSL: 14.01

Gujarat Kidney And Super Speciality  (NSE:GKSL) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=201.676/2525.122
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(201.676 / 1223.14)*(1223.14 / 2976.4)*(2976.4 / 2525.122)
=Net Margin %*Asset Turnover*Equity Multiplier
=16.49 %*0.4109*1.1787
=ROA %*Equity Multiplier
=6.78 %*1.1787
=7.99 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=201.676/2525.122
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (201.676 / 187.432) * (187.432 / 191.624) * (191.624 / 1223.14) * (1223.14 / 2976.4) * (2976.4 / 2525.122)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.076 * 0.9781 * 15.67 % * 0.4109 * 1.1787
=7.99 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Gujarat Kidney And Super Speciality ROE % Related Terms


Gujarat Kidney And Super Speciality ROE % Historical Data

* Premium members only.

The historical data trend for Gujarat Kidney And Super Speciality's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gujarat Kidney And Super Speciality ROE % Chart

Gujarat Kidney And Super Speciality Annual Data
Trend Mar23 Mar24 Mar25 Mar26
ROE %
30.22 43.79 30.91 10.65

Gujarat Kidney And Super Speciality Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
ROE % Get a 7-Day Free Trial 44.98 13.23 73.11 25.21 7.99

NSE:GKSL vs HCA, THC, DVA: ROE % Comparison

For the Medical Care Facilities subindustry, Gujarat Kidney And Super Speciality's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gujarat Kidney And Super Speciality ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Gujarat Kidney And Super Speciality's ROE % distribution charts can be found below:

* The bar in red indicates where Gujarat Kidney And Super Speciality's ROE % falls into.


NSE:GKSL
18GF Score
Gujarat Kidney And Super Speciality Ltd NSE:GKSL
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gujarat Kidney And Super Speciality ROE % Calculation

Gujarat Kidney And Super Speciality's annualized ROE % for the fiscal year that ended in Mar. 2026 is calculated as

ROE %=Net Income (A: Mar. 2026 )/( (Total Stockholders Equity (A: Mar. 2025 )+Total Stockholders Equity (A: Mar. 2026 ))/ count )
=154.969/( (386.396+2525.122)/ 2 )
=154.969/1455.759
=10.65 %

Gujarat Kidney And Super Speciality's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=201.676/( (0+2525.122)/ 1 )
=201.676/2525.122
=7.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 7.99% mean?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a ROE % of 7.99% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Gujarat Kidney And Super Speciality and its competitors. This is 74% below median its historical median of 30.57. Over the past decade, Gujarat Kidney And Super Speciality's ROE % has ranged from 10.65 to 43.79. According to the industry distribution chart, Gujarat Kidney And Super Speciality ranks #162 out of 625 companies in the Healthcare Providers & Services industry, placing it in the top 25.9%.
Is Gujarat Kidney And Super Speciality's ROE % too high?
Gujarat Kidney And Super Speciality's current ROE % of 7.99% is 74% below median its 10-year median of 30.57. Over the past 10 years, this metric has ranged from a low of 10.65 to a high of 43.79. The Healthcare Providers & Services industry median ROE % is 5.84. Gujarat Kidney And Super Speciality's value of 7.99% is 36.8% above this industry median. Based on the distribution chart, Gujarat Kidney And Super Speciality ranks #162 out of 625 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Gujarat Kidney And Super Speciality has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Gujarat Kidney And Super Speciality's ROE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Gujarat Kidney And Super Speciality ranks #162 out of 625 companies for ROE %. This puts Gujarat Kidney And Super Speciality in the upper half of its industry. The industry median ROE % is 5.84. Gujarat Kidney And Super Speciality's value of 7.99% is 36.8% above this benchmark. Historically, Gujarat Kidney And Super Speciality's own ROE % has ranged from 10.65 to 43.79 over the past decade. While the company's 10-year median is 30.57 vs. the industry median of 5.84, Gujarat Kidney And Super Speciality has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.84, based on 625 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Kidney And Super Speciality's current ROE % of 7.99% is 36.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Gujarat Kidney And Super Speciality and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Kidney And Super Speciality's current ROE % is 7.99%, which is 74% below median its own 10-year median of 30.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Kidney And Super Speciality stock overvalued right now?
Gujarat Kidney And Super Speciality (NSE:GKSL) has a current ROE % of 7.99%. The current ROE % is 7.99%, which is 74% below median its 10-year median of 30.57 and 36.8% above the Healthcare Providers & Services industry median of 5.84. Gujarat Kidney And Super Speciality's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Gujarat Kidney And Super Speciality (NSE:GKSL), the current ROE % is 7.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gujarat Kidney And Super Speciality Business Description

Other Exchanges 544666:India
Address Jetalpur Road, Gokak Mill Compound, Plot No. 1, City Sarve No. 1537/A, Jetalpur Bridge, Anand Nagar, Haripura, Alkapuri, Vadodara, GJ, IND, 390 020
Gujarat Kidney And Super Speciality Ltd is engaged in the business of operating a chain of mid-sized multispeciality hospitals in central Gujarat and providing integrated healthcare services, with a focus on secondary and tertiary care. It offers a range of healthcare services, including General Medicine, General Surgery, Laparoscopic Surgery, Urology, Cardiology, Nephrology, and many more. The company operates in a single segment, namely Medical and Healthcare Services. It generates a substantial portion of revenue from its services to inpatients. Geographically, it operates only in India.
18GF Score

Get the complete analysis for NSE:GKSL

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹129.23
Price